Healthcare Unusual Volume: STAAR Surgical Company (NASDAQ:STAA), pSivida Corp. (NASDAQ:PSDV), Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), IRIDEX Corporation (NASDAQ:IRIX), ImmuCell Corporation (NASDAQ:ICCC)

Zacks upgraded shares of STAAR Surgical Company (NASDAQ:STAA) from an underperform rating to a neutral rating in a research note released on Tuesday morning. They currently have $17.20 target price on the stock. STAAR Surgical Company (NASDAQ:STAA) net profit margin is -2.00% and weekly performance is -15.42%. On last trading day company shares ended up $13.85. Analysts mean target price for the company is $21.00. STAAR Surgical Company (NASDAQ:STAA) distance from 50-day simple moving average is -13.69%.

pSivida Corp. (Nasdaq:PSDV) announced that the regulatory process for marketing authorizations in Belgium, the Czech Republic, Denmark, Finland, Ireland, Luxembourg, the Netherlands, Norway, Poland and Sweden has entered the national phase following the successful completion of the Mutual Recognition Procedure (MRP) for subsequent authorizations. In the national phase, each of these countries will grant a marketing authorization for ILUVIEN for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. ILUVIEN initially received marketing authorizations in Austria, France, Italy, Portugal, Spain as well as the United Kingdom and Germany where it is now commercially available. pSivida Corp. (NASDAQ:PSDV) shares advanced 8.31% in last trading session and ended the day on $4.69. PSDV its return on assets is -62.10%. pSivida Corp. (NASDAQ:PSDV) quarterly performance is 11.40%.

On May 15, 2014 Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, reported unaudited first quarter fiscal year 2014 earnings, for the period ended March 31, 2014.Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) shares moved up 1.08% in last trading session and was closed at $7.48, while trading in range of $7.45-$8.00. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) year to date performance is 113.11%.

IRIDEX (NASDAQ:IRIX) Director Catalyst Fund Ix L.P Blueline purchased 7,390 shares of the stock on the open market in a transaction that occurred on Friday, June 6th. The shares were purchased at an average price of $8.32 per share, for a total transaction of $61,484.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission IRIDEX Corporation (NASDAQ:IRIX) ended the last trading day at $8.10. Company weekly volatility is calculated as 2.91% and price to cash ratio as 5.76. IRIDEX Corporation (NASDAQ:IRIX) showed a negative weekly performance of -3.69%.

——–ImmuCell Corporation (NASDAQ:ICCC) net profit margin is 1.60% and weekly performance is 2.88%. On last trading day company shares ended up $4.65. ImmuCell Corporation (NASDAQ:ICCC) distance from 50-day simple moving average is 11.68%.